tradingkey.logo
tradingkey.logo
Search

C4 Therapeutics Inc

CCCC
Add to Watchlist
3.480USD
-0.180-4.92%
Close 07-31 16:00ETQuotes delayed by 15 min
384.77MMarket Cap
LossP/E TTM

CCCC Income Statement

You can find the annual or quarterly income statement of C4 Therapeutics Inc here for insights into the performance and operational efficiency of C4 Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
Total revenue
-15.00%6.15M
112.79%11.02M
-26.90%11.23M
-46.17%6.46M
138.17%7.24M
58.75%5.18M
38.75%15.36M
350.68%12.01M
-19.15%3.04M
14.26%3.26M
63.93%11.07M
-80.74%2.66M
-50.89%3.76M
-85.79%2.85M
-20.54%6.75M
41.44%13.83M
3.07%7.65M
143.02%20.08M
0.63%8.50M
--9.78M
--7.43M
--8.26M
--8.45M
Revenue
-15.00%6.15M
112.79%11.02M
-26.90%11.23M
-46.17%6.46M
138.17%7.24M
58.75%5.18M
38.75%15.36M
350.68%12.01M
-19.15%3.04M
14.26%3.26M
63.93%11.07M
-80.74%2.66M
-50.89%3.76M
-85.79%2.85M
-20.54%6.75M
41.44%13.83M
3.07%7.65M
143.02%20.08M
0.63%8.50M
--9.78M
--7.43M
--8.26M
--8.45M
Operating expenses
-6.77%33.94M
-20.34%34.16M
-19.94%34.91M
4.53%34.96M
10.91%36.40M
5.40%42.89M
12.16%43.61M
-16.86%33.45M
-17.92%32.82M
-1.12%40.69M
-0.92%38.88M
-2.39%40.23M
2.47%39.99M
16.45%41.15M
19.81%39.24M
29.22%41.22M
39.69%39.02M
30.07%35.33M
22.23%32.75M
--31.90M
--27.93M
--27.16M
--26.80M
R&D expenses
-9.11%24.61M
-23.16%24.98M
-18.37%25.99M
10.29%26.20M
20.14%27.07M
6.98%32.51M
12.32%31.84M
-20.63%23.75M
-22.41%22.53M
-0.85%30.39M
-4.44%28.35M
-4.46%29.93M
10.83%29.04M
15.45%30.65M
22.06%29.66M
34.51%31.32M
27.66%26.20M
29.94%26.55M
4.14%24.30M
--23.29M
--20.53M
--20.43M
--23.34M
Depreciation, depletion, and amortization
-11.40%404.00K
-10.83%428.00K
4.07%460.00K
37.28%615.00K
1.79%456.00K
11.63%480.00K
-1.12%442.00K
-2.18%448.00K
-17.80%448.00K
-17.47%430.00K
7.71%447.00K
5.29%458.00K
78.69%545.00K
61.30%521.00K
25.76%415.00K
12.11%435.00K
-32.37%305.00K
-11.51%323.00K
-45.00%330.00K
--388.00K
--451.00K
--365.00K
--600.00K
Operating profit
4.73%-27.79M
38.62%-23.14M
16.16%-23.68M
-32.92%-28.50M
2.08%-29.16M
-0.75%-37.71M
-1.57%-28.24M
42.92%-21.44M
17.79%-29.78M
2.26%-37.43M
14.41%-27.81M
-37.19%-37.57M
-15.49%-36.23M
-151.02%-38.29M
-33.95%-32.49M
-23.82%-27.38M
-52.95%-31.37M
19.30%-15.26M
-32.18%-24.25M
---22.12M
---20.51M
---18.90M
---18.35M
Net non-operating interest income (expenses)
Non-operating interest income
-6.54%2.66M
-14.91%2.78M
-37.23%2.25M
-33.41%2.48M
-26.33%2.84M
10.75%3.27M
39.66%3.58M
65.89%3.73M
87.83%3.86M
72.62%2.95M
136.35%2.56M
343.87%2.25M
644.20%2.05M
1156.62%1.71M
885.45%1.08M
633.33%506.00K
283.33%276.00K
-78.14%136.00K
--110.00K
--69.00K
--72.00K
--622.00K
----
Non-operating interest expense
----
----
----
----
----
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-69.86%167.00K
12.36%600.00K
14.99%606.00K
11.50%601.00K
2.78%554.00K
0.19%534.00K
-1.31%527.00K
-49.10%539.00K
--539.00K
--533.00K
--534.00K
--1.06M
----
Special income (expenses)
----
--0.00
---10.73M
--0.00
100.00%0.00
--0.00
100.00%0.00
--0.00
---2.44M
--0.00
---621.00K
----
----
----
----
----
----
100.00%0.00
100.00%0.00
----
----
---2.54M
---3.14M
Other non-operating income (expenses)
----
--3.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
---44.00K
---160.00K
Income before tax
4.53%-25.13M
40.87%-20.36M
-30.41%-32.17M
-46.87%-26.02M
7.19%-26.32M
0.10%-34.44M
5.25%-24.67M
50.68%-17.72M
18.46%-28.36M
7.28%-34.48M
18.54%-26.03M
-31.04%-35.92M
-9.99%-34.78M
-137.48%-37.19M
-29.47%-31.96M
-21.40%-27.41M
-50.78%-31.62M
28.56%-15.66M
-12.19%-24.68M
---22.58M
---20.97M
---21.92M
---22.00M
Income tax
--0.00
-7.63%121.00K
--0.00
--0.00
--0.00
-52.71%131.00K
-100.00%0.00
----
----
--277.00K
--1.00M
----
----
----
----
----
--0.00
100.00%0.00
100.00%0.00
--0.00
--0.00
---124.00K
---167.00K
Income after tax
4.53%-25.13M
40.75%-20.49M
-30.41%-32.17M
-46.87%-26.02M
7.19%-26.32M
0.52%-34.57M
8.77%-24.67M
50.68%-17.72M
18.46%-28.36M
6.54%-34.75M
15.40%-27.04M
-31.04%-35.92M
-9.99%-34.78M
-137.48%-37.19M
-29.47%-31.96M
-21.40%-27.41M
-50.78%-31.62M
28.16%-15.66M
-13.04%-24.68M
---22.58M
---20.97M
---21.80M
---21.84M
Net income from continuous operations
4.53%-25.13M
40.75%-20.49M
-30.41%-32.17M
-46.87%-26.02M
7.19%-26.32M
0.52%-34.57M
8.77%-24.67M
50.68%-17.72M
18.46%-28.36M
6.54%-34.75M
15.40%-27.04M
-31.04%-35.92M
-9.99%-34.78M
-137.48%-37.19M
-29.47%-31.96M
-21.40%-27.41M
-50.78%-31.62M
28.16%-15.66M
-13.04%-24.68M
---22.58M
---20.97M
---21.80M
---21.84M
Net income attributable to controlling interests
4.53%-25.13M
40.75%-20.49M
-30.41%-32.17M
-46.87%-26.02M
7.19%-26.32M
0.52%-34.57M
8.77%-24.67M
50.68%-17.72M
18.46%-28.36M
6.54%-34.75M
15.40%-27.04M
-31.04%-35.92M
-9.99%-34.78M
-137.48%-37.19M
-29.47%-31.96M
-21.40%-27.41M
-50.78%-31.62M
-36.97%-15.66M
8.74%-24.68M
---22.58M
---20.97M
---11.43M
---27.05M
Preferred share dividend
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
-100.00%0.00
--0.00
--0.00
----
--5.21M
Net income attributable to common shareholders
4.53%-25.13M
40.75%-20.49M
-30.41%-32.17M
-46.87%-26.02M
7.19%-26.32M
0.52%-34.57M
8.77%-24.67M
50.68%-17.72M
18.46%-28.36M
6.54%-34.75M
15.40%-27.04M
-31.04%-35.92M
-9.99%-34.78M
-137.48%-37.19M
-29.47%-31.96M
-21.40%-27.41M
-50.78%-31.62M
-36.97%-15.66M
8.74%-24.68M
---22.58M
---20.97M
---11.43M
---27.05M
Basic earnings per share
46.36%-0.20
64.29%-0.17
-25.13%-0.44
-42.33%-0.37
10.33%-0.37
27.80%-0.49
35.52%-0.35
64.84%-0.26
41.57%-0.41
10.71%-0.68
15.90%-0.55
-30.40%-0.73
-9.33%-0.71
-136.09%-0.76
-28.33%-0.65
-9.05%-0.56
-33.30%-0.65
-21.16%-0.32
21.81%-0.51
---0.51
---0.49
---0.27
---0.65
Diluted earnings per share
46.36%-0.20
64.29%-0.17
-25.13%-0.44
-42.33%-0.37
10.33%-0.37
27.80%-0.49
35.52%-0.35
64.84%-0.26
41.57%-0.41
10.71%-0.68
15.90%-0.55
-30.40%-0.73
-9.33%-0.71
-136.09%-0.76
-28.33%-0.65
-9.05%-0.56
-33.30%-0.65
-21.16%-0.32
21.81%-0.51
---0.51
---0.49
---0.27
---0.65
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read C4 Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing CCCC stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was C4 Therapeutics Inc's revenue at year end?

C4 Therapeutics Inc reported 35.95M in revenue for fiscal year 2025, up from 35.58M in the previous year.

How much revenue did C4 Therapeutics Inc report in the most recent quarter?

C4 Therapeutics Inc reported 6.15M in revenue for the most recent quarter, an increase of -15.00% year over year.

What was C4 Therapeutics Inc's net income for the year?

C4 Therapeutics Inc posted -104.99M in net income for fiscal year 2025.

How much net income did C4 Therapeutics Inc post in the last quarter?

C4 Therapeutics Inc reported -25.13M in net income for the latest quarter。

What was C4 Therapeutics Inc's annual operating profit?

C4 Therapeutics Inc's operating income was -104.49M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.